Total vaccine sales were down due to lower sales of Arexvy and Shingrix ... We have a strong balance sheet, which provides optionality to accelerate further growth organically and through business ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ...

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data. Arexvy is ...

RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 ... They are neither statements of historical ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...